Literature DB >> 21200404

A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response.

Suzanne Paz1, Myriam Vilasco, Steven J Werden, Meztli Arguello, Deshanthe Joseph-Pillai, Tiejun Zhao, Thi Lien-Anh Nguyen, Qiang Sun, Eliane F Meurs, Rongtuan Lin, John Hiscott.   

Abstract

Recognition of viral RNA structures by the cytosolic sensor retinoic acid-inducible gene-I (RIG-I) results in the activation of signaling cascades that culminate with the generation of the type I interferon (IFN) antiviral response. Onset of antiviral and inflammatory responses to viral pathogens necessitates the regulated spatiotemporal recruitment of signaling adapters, kinases and transcriptional proteins to the mitochondrial antiviral signaling protein (MAVS). We previously demonstrated that the serine/threonine kinase IKKε is recruited to the C-terminal region of MAVS following Sendai or vesicular stomatitis virus (VSV) infection, mediated by Lys63-linked polyubiquitination of MAVS at Lys500, resulting in inhibition of downstream IFN signaling (Paz et al, Mol Cell Biol, 2009). In this study, we demonstrate that C-terminus of MAVS harbors a novel TRAF3-binding site in the aa450-468 region of MAVS. A consensus TRAF-interacting motif (TIM), 455-PEENEY-460, within this site is required for TRAF3 binding and activation of IFN antiviral response genes, whereas mutation of the TIM eliminates TRAF3 binding and the downstream IFN response. Reconstitution of MAVS(-/-) mouse embryo fibroblasts with a construct expressing a TIM-mutated version of MAVS failed to restore the antiviral response or block VSV replication, whereas wild-type MAVS reconstituted antiviral inhibition of VSV replication. Furthermore, recruitment of IKKε to an adjacent C-terminal site (aa 468-540) in MAVS via Lys500 ubiquitination decreased TRAF3 binding and protein stability, thus contributing to IKKε-mediated shutdown of the IFN response. This study demonstrates that MAVS harbors a functional C-terminal TRAF3-binding site that participates in positive and negative regulation of the IFN antiviral response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21200404      PMCID: PMC3203699          DOI: 10.1038/cr.2011.2

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  72 in total

1.  TRAF6 and MEKK1 play a pivotal role in the RIG-I-like helicase antiviral pathway.

Authors:  Ryoko Yoshida; Giichi Takaesu; Hideyuki Yoshida; Fuyuki Okamoto; Tomoko Yoshioka; Yongwon Choi; Shizuo Akira; Taro Kawai; Akihiko Yoshimura; Takashi Kobayashi
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

2.  FLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway.

Authors:  Takahito Sanada; Giichi Takaesu; Ryuichi Mashima; Ryoko Yoshida; Takashi Kobayashi; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2008-10-10       Impact factor: 5.157

3.  The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation.

Authors:  Bo Zhong; Yan Yang; Shu Li; Yan-Yi Wang; Ying Li; Feici Diao; Caoqi Lei; Xiao He; Lu Zhang; Po Tien; Hong-Bing Shu
Journal:  Immunity       Date:  2008-09-25       Impact factor: 31.745

4.  MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2.

Authors:  Jin Hou; Pin Wang; Li Lin; Xingguang Liu; Feng Ma; Huazhang An; Zhugang Wang; Xuetao Cao
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

5.  Ubiquitin-regulated recruitment of IkappaB kinase epsilon to the MAVS interferon signaling adapter.

Authors:  Suzanne Paz; Myriam Vilasco; Meztli Arguello; Qiang Sun; Judith Lacoste; Thi Lien-Anh Nguyen; Tiejun Zhao; Elena A Shestakova; Scott Zaari; Annie Bibeau-Poirier; Marc J Servant; Rongtuan Lin; Eliane F Meurs; John Hiscott
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

6.  MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease.

Authors:  Martin Baril; Marie-Eve Racine; François Penin; Daniel Lamarre
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

7.  ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization.

Authors:  Wenxiang Sun; Yang Li; Lu Chen; Huihui Chen; Fuping You; Xiang Zhou; Yi Zhou; Zhonghe Zhai; Danying Chen; Zhengfan Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

8.  Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR at mitochondria.

Authors:  Lijuan Xu; Nengming Xiao; Feng Liu; Hongwei Ren; Jun Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

9.  MAVS self-association mediates antiviral innate immune signaling.

Authors:  Eric D Tang; Cun-Yu Wang
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling.

Authors:  Hiroki Ishikawa; Glen N Barber
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

View more
  73 in total

1.  IκB kinase ε-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis.

Authors:  Peyman Nakhaei; Qiang Sun; Mayra Solis; Thibault Mesplede; Eric Bonneil; Suzanne Paz; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  A non-canonical role of the p97 complex in RIG-I antiviral signaling.

Authors:  Qian Hao; Shi Jiao; Zhubing Shi; Chuanchuan Li; Xia Meng; Zhen Zhang; Yanyan Wang; Xiaomin Song; Wenjia Wang; Rongguang Zhang; Yun Zhao; Catherine C L Wong; Zhaocai Zhou
Journal:  EMBO J       Date:  2015-10-15       Impact factor: 11.598

Review 3.  Mechanisms of MAVS regulation at the mitochondrial membrane.

Authors:  Jana L Jacobs; Carolyn B Coyne
Journal:  J Mol Biol       Date:  2013-10-09       Impact factor: 5.469

4.  Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78.

Authors:  Jana L Jacobs; Jianzhong Zhu; Saumendra N Sarkar; Carolyn B Coyne
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

Review 5.  MDA5 and LGP2: accomplices and antagonists of antiviral signal transduction.

Authors:  Kenny R Rodriguez; Annie M Bruns; Curt M Horvath
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 6.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 7.  Expanding TRAF function: TRAF3 as a tri-faced immune regulator.

Authors:  Hans Häcker; Ping-Hui Tseng; Michael Karin
Journal:  Nat Rev Immunol       Date:  2011-06-10       Impact factor: 53.106

8.  Structural Insights into mitochondrial antiviral signaling protein (MAVS)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling.

Authors:  Zhubing Shi; Zhen Zhang; Zhenzhen Zhang; Yanyan Wang; Chuanchuan Li; Xin Wang; Feng He; Lina Sun; Shi Jiao; Weiyang Shi; Zhaocai Zhou
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

9.  The small GTPase RAB1B promotes antiviral innate immunity by interacting with TNF receptor-associated factor 3 (TRAF3).

Authors:  Dia C Beachboard; Moonhee Park; Madhuvanthi Vijayan; Daltry L Snider; Dillon J Fernando; Graham D Williams; Sydney Stanley; Michael J McFadden; Stacy M Horner
Journal:  J Biol Chem       Date:  2019-08-02       Impact factor: 5.157

10.  Parkin negatively regulates the antiviral signaling pathway by targeting TRAF3 for degradation.

Authors:  Di Xin; Haiyan Gu; Enping Liu; Qinmiao Sun
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.